• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

胃腺癌多学科治疗的现状

CURRENT STATUS OF THE MULTIDISCIPLINARY TREATMENT OF GASTRIC ADENOCARCINOMA.

作者信息

Toneto Marcelo Garcia, Viola Luciana

机构信息

Escola de Medicina, Pontifícia Universidade Católica do Rio Grande do Sul - PUCRS, Porto Alegre, RS, Brazil.

出版信息

Arq Bras Cir Dig. 2018;31(2):e1373. doi: 10.1590/0102-672020180001e1373. Epub 2018 Jul 2.

DOI:10.1590/0102-672020180001e1373
PMID:29972401
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6044205/
Abstract

BACKGROUND

The complexity of the management of gastric cancer requires a multidisciplinary evaluation of patients with this tumor. Several treatments have been employed, associated to the surgical resection.

OBJECTIVE

To review the available therapeutic alternatives for the treatment of gastric adenocarcinoma.

METHODS

A review of selected articles on multidisciplinary treatment of gastric adenocarcinoma in the Pubmed and Medline databases between 2000 and 2017 was carried out. The following headings were related: stomach cancer, treatment, chemotherapy and radiotherapy.

RESULTS

There are several valid alternatives, with good results for the treatment of gastric cancer: chemoradiotherapy or chemotherapy in the adjuvant scenario; perioperative chemotherapy; and chemoradiotherapy after neoadjuvance with isolated chemotherapy.

CONCLUSION

Current evidences suggest that combined multidisciplinary treatment is superior to surgery alone. However, the optimal treatment regimen is not yet established, and depends on a number of factors, especially the type of surgical resection employed. Therefore, the therapeutic decision should be made by a multidisciplinary team, assessing patient's personal characteristics, biology of the tumor, residual disease, risks and side effects.

摘要

背景

胃癌治疗的复杂性要求对患有这种肿瘤的患者进行多学科评估。已经采用了几种与手术切除相关的治疗方法。

目的

回顾治疗胃腺癌的可用治疗选择。

方法

对2000年至2017年期间在Pubmed和Medline数据库中关于胃腺癌多学科治疗的选定文章进行了综述。相关的主题如下:胃癌、治疗、化疗和放疗。

结果

有几种有效的治疗选择,对胃癌的治疗效果良好:辅助治疗中的放化疗或化疗;围手术期化疗;以及在新辅助化疗后单独化疗后进行放化疗。

结论

目前的证据表明,多学科联合治疗优于单纯手术治疗。然而,最佳治疗方案尚未确定,并且取决于许多因素,特别是所采用的手术切除类型。因此,治疗决策应由多学科团队做出,评估患者的个人特征、肿瘤生物学、残留疾病、风险和副作用。

相似文献

1
CURRENT STATUS OF THE MULTIDISCIPLINARY TREATMENT OF GASTRIC ADENOCARCINOMA.胃腺癌多学科治疗的现状
Arq Bras Cir Dig. 2018;31(2):e1373. doi: 10.1590/0102-672020180001e1373. Epub 2018 Jul 2.
2
Expert opinion on management of gastric and gastro-oesophageal junction adenocarcinoma on behalf of the European Organisation for Research and Treatment of Cancer (EORTC)-gastrointestinal cancer group.代表欧洲癌症研究与治疗组织(EORTC)胃肠癌小组对胃及胃食管交界腺癌管理的专家意见。
Eur J Cancer. 2008 Jan;44(2):182-94. doi: 10.1016/j.ejca.2007.11.001.
3
Perioperative chemo(radio)therapy versus primary surgery for resectable adenocarcinoma of the stomach, gastroesophageal junction, and lower esophagus.可切除的胃、胃食管交界部和食管下段腺癌的围手术期化疗(放疗)与初次手术对比
Cochrane Database Syst Rev. 2013 May 31;2013(5):CD008107. doi: 10.1002/14651858.CD008107.pub2.
4
Role of Chemotherapy and Radiation Therapy in the Management of Gastric Adenocarcinoma.
Surg Clin North Am. 2017 Apr;97(2):421-435. doi: 10.1016/j.suc.2016.11.013.
5
[Role of postoperative chemoradiotherapy in the therapeutic management of adenocarcinomas of the stomach and oesogastric junction].[术后放化疗在胃及食管胃交界腺癌治疗管理中的作用]
Cancer Radiother. 2016 Dec;20(8):830-832. doi: 10.1016/j.canrad.2016.07.100. Epub 2016 Oct 25.
6
Updates on Management of Gastric Cancer.胃癌治疗进展。
Curr Oncol Rep. 2019 Jun 24;21(8):67. doi: 10.1007/s11912-019-0820-4.
7
Perspectives in adjuvant therapy of gastric cancer.胃癌辅助治疗的观点。
Oncology. 2009;77 Suppl 1:38-42. doi: 10.1159/000258494. Epub 2010 Feb 2.
8
Chemoradiation therapy versus chemotherapy alone for gastric cancer after R0 surgical resection: a meta-analysis of randomized trials.R0 手术后胃癌行放化疗与单纯化疗的比较:随机试验的荟萃分析。
Oncology. 2014;86(2):79-85. doi: 10.1159/000354641. Epub 2014 Jan 15.
9
Treatment in resectable non-metastatic adenocarcinoma of stomach: Changing paradigms.
Indian J Cancer. 2019 Jan-Mar;56(1):74-80. doi: 10.4103/ijc.IJC_375_18.
10
Processes of care in the multidisciplinary treatment of gastric cancer: results of a RAND/UCLA expert panel.多学科治疗胃癌的护理流程:RAND/UCLA 专家小组的研究结果。
JAMA Surg. 2014 Jan;149(1):18-25. doi: 10.1001/jamasurg.2013.3959.

引用本文的文献

1
Association of Sijunzi decoction plus chemotherapy with gastrointestinal function and serum markers in patients after gastric carcinoma surgery.四君子汤加化疗对胃癌术后患者胃肠功能及血清标志物的影响
World J Gastrointest Surg. 2025 Apr 27;17(4):100800. doi: 10.4240/wjgs.v17.i4.100800.
2
Effects of high-quality nursing intervention on negative emotions, postoperative complications and gastrointestinal function in patients with gastric cancer surgery.优质护理干预对胃癌手术患者负性情绪、术后并发症及胃肠功能的影响
Am J Transl Res. 2022 Mar 15;14(3):1652-1662. eCollection 2022.
3
LYMPHOPARIETAL INDEX IN ESOPHAGEAL CANCER IS STRONGER THAN TNM STAGING IN LONG-TERM SURVIVAL PROGNOSIS IN A LATIN-AMERICAN COUNTRY.在拉丁美洲国家,食管癌的淋巴旁指数比 TNM 分期在长期生存预后方面更强。
Arq Bras Cir Dig. 2021 Jan 15;33(3):e1547. doi: 10.1590/0102-672020200003e1547. eCollection 2021.
4
BRAZILIAN GASTRIC CANCER ASSOCIATION GUIDELINES (PART 1): AN UPDATE ON DIAGNOSIS, STAGING, ENDOSCOPIC TREATMENT AND FOLLOW-UP.巴西胃癌协会指南(第1部分):诊断、分期、内镜治疗及随访的最新进展
Arq Bras Cir Dig. 2020 Dec 18;33(3):e1535. doi: 10.1590/0102-672020200003e1535. eCollection 2020.
5
TRANSHIATAL ESOPHAGECTOMY IS NOT ASSOCIATED WITH POOR QUALITY LYMPHADENECTOMY.经胸食管切除术与淋巴结清扫质量不佳无关。
Arq Bras Cir Dig. 2019 Dec 20;32(4):e1475. doi: 10.1590/0102-672020190001e1475. eCollection 2019.
6
Impact of perioperative treatment on survival of resectable gastric cancer patients after D2 lymphadenectomy: a single European centre propensity score matching analysis.围手术期治疗对D2淋巴结清扫术后可切除胃癌患者生存的影响:一项欧洲单中心倾向评分匹配分析
Radiol Oncol. 2019 May 8;53(2):245-255. doi: 10.2478/raon-2019-0019.
7
TOTAL OMENTECTOMY IN GASTRIC CANCER SURGERY: IS IT ALWAYS NECESSARY?胃癌手术中的全网膜切除术:是否总是必要?
Arq Bras Cir Dig. 2019 Feb 7;32(1):e1425. doi: 10.1590/0102-672020180001e1425.

本文引用的文献

1
Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trial.新辅助多西他赛、奥沙利铂、氟尿嘧啶和亚叶酸钙与表柔比星、顺铂和氟尿嘧啶或卡培他滨用于可切除胃或胃食管交界处腺癌患者(FLOT4-AIO):多中心、开放标签、随机 2/3 期临床试验 2 期部分的结果。
Lancet Oncol. 2016 Dec;17(12):1697-1708. doi: 10.1016/S1470-2045(16)30531-9. Epub 2016 Oct 22.
2
Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.胃癌:ESMO 诊断、治疗及随访临床实践指南
Ann Oncol. 2016 Sep;27(suppl 5):v38-v49. doi: 10.1093/annonc/mdw350.
3
Gastrectomy plus chemotherapy versus chemotherapy alone for advanced gastric cancer with a single non-curable factor (REGATTA): a phase 3, randomised controlled trial.胃切除术加化疗与单纯化疗治疗有单一不可治愈因素的晚期胃癌(REGATTA):一项 3 期随机对照试验。
Lancet Oncol. 2016 Mar;17(3):309-318. doi: 10.1016/S1470-2045(15)00553-7. Epub 2016 Jan 26.
4
Current status of management of malignant disease: current management of gastric cancer.恶性疾病的管理现状:胃癌的当前管理
J Gastrointest Surg. 2015 Apr;19(4):782-8. doi: 10.1007/s11605-014-2707-x. Epub 2015 Jan 16.
5
Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomised phase 3 trial.卡培他滨联合奥沙利铂辅助治疗 D2 胃切除术后胃癌(CLASSIC):一项开放标签、随机、3 期临床试验的 5 年随访结果。
Lancet Oncol. 2014 Nov;15(12):1389-96. doi: 10.1016/S1470-2045(14)70473-5. Epub 2014 Oct 15.
6
Brazilian consensus in gastric cancer: guidelines for gastric cancer in Brazil.巴西胃癌共识:巴西胃癌指南
Arq Bras Cir Dig. 2013 Jan-Mar;26(1):2-6. doi: 10.1590/s0102-67202013000100002.
7
Updated analysis of SWOG-directed intergroup study 0116: a phase III trial of adjuvant radiochemotherapy versus observation after curative gastric cancer resection.SWOG 指导的分组研究 0116 的更新分析:辅助放化疗与根治性胃癌切除术后观察的 III 期临床试验。
J Clin Oncol. 2012 Jul 1;30(19):2327-33. doi: 10.1200/JCO.2011.36.7136. Epub 2012 May 14.
8
Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial.卡培他滨和奥沙利铂辅助治疗 D2 胃切除术后胃癌(CLASSIC):一项开放标签、随机对照 3 期临床试验。
Lancet. 2012 Jan 28;379(9813):315-21. doi: 10.1016/S0140-6736(11)61873-4. Epub 2012 Jan 7.
9
Phase III trial comparing capecitabine plus cisplatin versus capecitabine plus cisplatin with concurrent capecitabine radiotherapy in completely resected gastric cancer with D2 lymph node dissection: the ARTIST trial.III 期临床试验比较卡培他滨联合顺铂与卡培他滨联合顺铂同步卡培他滨放疗在完全切除胃腺癌且行 D2 淋巴结清扫术后的疗效:ARTIST 试验。
J Clin Oncol. 2012 Jan 20;30(3):268-73. doi: 10.1200/JCO.2011.39.1953. Epub 2011 Dec 19.
10
Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer.一项比较辅助化疗 S-1 与单纯手术治疗 II 期或 III 期胃癌的随机 III 期临床试验的 5 年结果。
J Clin Oncol. 2011 Nov 20;29(33):4387-93. doi: 10.1200/JCO.2011.36.5908. Epub 2011 Oct 17.